electroCore, Inc. (NASDAQ: ECOR) Stock Competitors & Peer Comparison
See ECOR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ECOR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ECOR | $11.68 | +2.64% | 105.3M | -6.95 | -$1.68 | N/A |
| ABT | $102.61 | +0.37% | 177.4B | 19.68 | $5.21 | +2.42% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $92.13 | -0.69% | 118B | 16.66 | $5.53 | +3.08% |
| SYK | $275.12 | -1.79% | 105.4B | 20.54 | $13.39 | +1.26% |
| BSX | $43.34 | -0.48% | 64.5B | 14.00 | $3.10 | N/A |
| EW | $88.26 | +0.01% | 50.8B | 32.69 | $2.70 | N/A |
| DXCM | $89.35 | +1.61% | 33.7B | 35.04 | $2.55 | N/A |
| GEHC | $64.13 | -0.49% | 29B | 14.06 | $4.56 | +0.22% |
| PHG | $24.68 | +0.00% | 24.1B | 14.10 | $1.75 | +4.01% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
ECOR vs ABT Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ABT has a market cap of 177.4B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ABT trades at $102.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ABT's P/E ratio is 19.68. In terms of profitability, ECOR's ROE is +5.25%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
ECOR vs BSX-PA Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ECOR's ROE is +5.25%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
ECOR vs MDT Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, MDT has a market cap of 118B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while MDT trades at $92.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas MDT's P/E ratio is 16.66. In terms of profitability, ECOR's ROE is +5.25%, compared to MDT's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
ECOR vs SYK Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SYK has a market cap of 105.4B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SYK trades at $275.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SYK's P/E ratio is 20.54. In terms of profitability, ECOR's ROE is +5.25%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ECOR is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
ECOR vs BSX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BSX has a market cap of 64.5B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BSX trades at $43.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BSX's P/E ratio is 14.00. In terms of profitability, ECOR's ROE is +5.25%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ECOR vs EW Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, EW has a market cap of 50.8B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while EW trades at $88.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas EW's P/E ratio is 32.69. In terms of profitability, ECOR's ROE is +5.25%, compared to EW's ROE of +0.10%. Regarding short-term risk, ECOR is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ECOR vs DXCM Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, DXCM has a market cap of 33.7B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while DXCM trades at $89.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas DXCM's P/E ratio is 35.04. In terms of profitability, ECOR's ROE is +5.25%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ECOR is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
ECOR vs GEHC Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, GEHC has a market cap of 29B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while GEHC trades at $64.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas GEHC's P/E ratio is 14.06. In terms of profitability, ECOR's ROE is +5.25%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ECOR vs PHG Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, PHG has a market cap of 24.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while PHG trades at $24.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas PHG's P/E ratio is 14.10. In terms of profitability, ECOR's ROE is +5.25%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ECOR is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ECOR vs ZBH Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ZBH has a market cap of 18.4B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ZBH trades at $95.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ZBH's P/E ratio is 11.25. In terms of profitability, ECOR's ROE is +5.25%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ECOR is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ECOR vs ABMD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ECOR's ROE is +5.25%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ECOR is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ECOR vs SWAV Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ECOR's ROE is +5.25%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ECOR is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
ECOR vs PEN Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while PEN trades at $317.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas PEN's P/E ratio is 82.93. In terms of profitability, ECOR's ROE is +5.25%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
ECOR vs SNN Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SNN has a market cap of 11.6B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SNN trades at $27.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SNN's P/E ratio is 12.97. In terms of profitability, ECOR's ROE is +5.25%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ECOR is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ECOR vs ALGN Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ALGN has a market cap of 10.7B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ALGN trades at $147.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ALGN's P/E ratio is 13.65. In terms of profitability, ECOR's ROE is +5.25%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ECOR is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ECOR vs BIO-B Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BIO-B has a market cap of 10.6B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BIO-B trades at $385.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BIO-B's P/E ratio is -67.94. In terms of profitability, ECOR's ROE is +5.25%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ECOR is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ECOR vs BIO Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BIO has a market cap of 10.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BIO trades at $376.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BIO's P/E ratio is 40.53. In terms of profitability, ECOR's ROE is +5.25%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ECOR is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
ECOR vs GMED Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, GMED has a market cap of 10B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while GMED trades at $74.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas GMED's P/E ratio is 16.69. In terms of profitability, ECOR's ROE is +5.25%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ECOR is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check GMED's competition here
Insulet Corp. (NASDAQ: PODD)
ECOR vs PODD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, PODD has a market cap of 9.7B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while PODD trades at $140.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas PODD's P/E ratio is 23.95. In terms of profitability, ECOR's ROE is +5.25%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ECOR is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PODD's competition here
Glaukos Corporation (NYSE: GKOS)
ECOR vs GKOS Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, GKOS has a market cap of 9.7B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while GKOS trades at $163.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas GKOS's P/E ratio is -190.27. In terms of profitability, ECOR's ROE is +5.25%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ECOR is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check GKOS's competition here
Masimo Corporation (NASDAQ: MASI)
ECOR vs MASI Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas MASI's P/E ratio is 44.43. In terms of profitability, ECOR's ROE is +5.25%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ECOR is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
ECOR vs BRKR Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BRKR has a market cap of 9.3B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BRKR trades at $61.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BRKR's P/E ratio is 30.85. In terms of profitability, ECOR's ROE is +5.25%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ECOR is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
ECOR vs BRKRP Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BRKRP has a market cap of 9B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BRKRP trades at $447.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BRKRP's P/E ratio is 245.01. In terms of profitability, ECOR's ROE is +5.25%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, ECOR is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
ECOR vs HAE Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while HAE trades at $108.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas HAE's P/E ratio is 21.66. In terms of profitability, ECOR's ROE is +5.25%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ECOR vs NARI Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas NARI's P/E ratio is -59.24. In terms of profitability, ECOR's ROE is +5.25%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ECOR is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
ECOR vs ITGR Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ITGR trades at $126.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ITGR's P/E ratio is 19.90. In terms of profitability, ECOR's ROE is +5.25%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ECOR is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
ECOR vs LIVN Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while LIVN trades at $78.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas LIVN's P/E ratio is 18.53. In terms of profitability, ECOR's ROE is +5.25%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check LIVN's competition here
Axonics, Inc. (NASDAQ: AXNX)
ECOR vs AXNX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ECOR's ROE is +5.25%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ECOR is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AXNX's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ECOR vs IRTC Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while IRTC trades at $109.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas IRTC's P/E ratio is -254.26. In terms of profitability, ECOR's ROE is +5.25%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ECOR is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check IRTC's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ECOR vs TMDX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while TMDX trades at $86.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas TMDX's P/E ratio is 43.87. In terms of profitability, ECOR's ROE is +5.25%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ECOR is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
ECOR vs NEOG Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, NEOG has a market cap of 2.8B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while NEOG trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas NEOG's P/E ratio is 46.39. In terms of profitability, ECOR's ROE is +5.25%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, ECOR is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NEOG's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ECOR vs AXGN Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, AXGN has a market cap of 2.4B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while AXGN trades at $44.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas AXGN's P/E ratio is 116.39. In terms of profitability, ECOR's ROE is +5.25%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ECOR is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ECOR vs INSP Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, INSP has a market cap of 2.2B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while INSP trades at $76.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas INSP's P/E ratio is 33.84. In terms of profitability, ECOR's ROE is +5.25%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ECOR is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check INSP's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ECOR vs UFPT Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, UFPT has a market cap of 2.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while UFPT trades at $276.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas UFPT's P/E ratio is 28.26. In terms of profitability, ECOR's ROE is +5.25%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ECOR is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ECOR vs BFLY Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BFLY has a market cap of 2.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BFLY trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BFLY's P/E ratio is -32.81. In terms of profitability, ECOR's ROE is +5.25%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ECOR is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check BFLY's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ECOR vs NUVA Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ECOR's ROE is +5.25%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ECOR is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ECOR vs ESTA Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ESTA trades at $69.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ESTA's P/E ratio is -55.00. In terms of profitability, ECOR's ROE is +5.25%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ECOR is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
ECOR vs NVCR Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while NVCR trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas NVCR's P/E ratio is -12.84. In terms of profitability, ECOR's ROE is +5.25%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ECOR is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ECOR vs ATEC Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ATEC trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ATEC's P/E ratio is -169.67. In terms of profitability, ECOR's ROE is +5.25%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ECOR is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
ECOR vs CNMD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while CNMD trades at $45.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas CNMD's P/E ratio is 10.00. In terms of profitability, ECOR's ROE is +5.25%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ECOR is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
ECOR vs HSKA Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ECOR's ROE is +5.25%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ECOR is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ECOR vs IART Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while IART trades at $15.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas IART's P/E ratio is 6.45. In terms of profitability, ECOR's ROE is +5.25%, compared to IART's ROE of -0.01%. Regarding short-term risk, ECOR is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ECOR vs AVNS Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ECOR's ROE is +5.25%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ECOR is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ECOR vs TNDM Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while TNDM trades at $16.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas TNDM's P/E ratio is -18.14. In terms of profitability, ECOR's ROE is +5.25%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ECOR is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TNDM's competition here
Artivion, Inc. (NYSE: AORT)
ECOR vs AORT Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while AORT trades at $23.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas AORT's P/E ratio is 38.85. In terms of profitability, ECOR's ROE is +5.25%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ECOR is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AORT's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ECOR vs SILK Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SILK's P/E ratio is -18.96. In terms of profitability, ECOR's ROE is +5.25%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ECOR is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
ECOR vs FNA Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas FNA's P/E ratio is -19.83. In terms of profitability, ECOR's ROE is +5.25%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ECOR is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check FNA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ECOR vs PRCT Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while PRCT trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas PRCT's P/E ratio is -9.95. In terms of profitability, ECOR's ROE is +5.25%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ECOR is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ECOR vs LMRI Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while LMRI trades at $11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas LMRI's P/E ratio is -21.56. In terms of profitability, ECOR's ROE is +5.25%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ECOR is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check LMRI's competition here
IRadimed Corporation (NASDAQ: IRMD)
ECOR vs IRMD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, IRMD has a market cap of 1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while IRMD trades at $82.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas IRMD's P/E ratio is 41.27. In terms of profitability, ECOR's ROE is +5.25%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ECOR is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check IRMD's competition here
Enovis Corporation (NYSE: ENOV)
ECOR vs ENOV Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ENOV trades at $18.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ENOV's P/E ratio is 5.17. In terms of profitability, ECOR's ROE is +5.25%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ECOR is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ENOV's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ECOR vs BBNX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BBNX has a market cap of 984.8M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BBNX trades at $21.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BBNX's P/E ratio is -13.27. In terms of profitability, ECOR's ROE is +5.25%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ECOR is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check BBNX's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ECOR vs CBLL Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, CBLL has a market cap of 924.7M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while CBLL trades at $24.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas CBLL's P/E ratio is -13.85. In terms of profitability, ECOR's ROE is +5.25%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ECOR is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
ECOR vs BVS Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BVS has a market cap of 874.6M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BVS trades at $12.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BVS's P/E ratio is 16.99. In terms of profitability, ECOR's ROE is +5.25%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ECOR is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check BVS's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ECOR vs CSII Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas CSII's P/E ratio is -20.83. In terms of profitability, ECOR's ROE is +5.25%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ECOR is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CSII's competition here
InMode Ltd. (NASDAQ: INMD)
ECOR vs INMD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, INMD has a market cap of 824.8M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while INMD trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas INMD's P/E ratio is 9.97. In terms of profitability, ECOR's ROE is +5.25%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ECOR is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check INMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ECOR vs SIBN Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SIBN has a market cap of 802.3M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SIBN trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SIBN's P/E ratio is -53.21. In terms of profitability, ECOR's ROE is +5.25%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ECOR is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SIBN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ECOR vs AVR Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, AVR has a market cap of 793.4M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while AVR trades at $8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas AVR's P/E ratio is -4.21. In terms of profitability, ECOR's ROE is +5.25%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ECOR is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check AVR's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ECOR vs VREX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, VREX has a market cap of 778.4M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while VREX trades at $18.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas VREX's P/E ratio is 19.46. In terms of profitability, ECOR's ROE is +5.25%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ECOR is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ECOR vs AHCO Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, AHCO has a market cap of 776.9M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while AHCO trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas AHCO's P/E ratio is 11.65. In terms of profitability, ECOR's ROE is +5.25%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ECOR is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AHCO's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ECOR vs CTKB Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, CTKB has a market cap of 684.5M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while CTKB trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas CTKB's P/E ratio is -28.08. In terms of profitability, ECOR's ROE is +5.25%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ECOR is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CTKB's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ECOR vs SSII Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SSII has a market cap of 652.4M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SSII trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SSII's P/E ratio is -63.58. In terms of profitability, ECOR's ROE is +5.25%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ECOR is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ECOR vs SRDX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ECOR's ROE is +5.25%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ECOR is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SRDX's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ECOR vs APEN Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas APEN's P/E ratio is -9.43. In terms of profitability, ECOR's ROE is +5.25%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ECOR is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ECOR vs KIDS Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, KIDS has a market cap of 560.4M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while KIDS trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas KIDS's P/E ratio is -18.49. In terms of profitability, ECOR's ROE is +5.25%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ECOR is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ECOR vs DCTH Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, DCTH has a market cap of 556.1M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while DCTH trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas DCTH's P/E ratio is 1611.00. In terms of profitability, ECOR's ROE is +5.25%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ECOR is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ECOR vs ZIMV Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ECOR's ROE is +5.25%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ECOR is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
ECOR vs CERS Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, CERS has a market cap of 534M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while CERS trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas CERS's P/E ratio is -52.89. In terms of profitability, ECOR's ROE is +5.25%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ECOR is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ECOR vs TCMD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, TCMD has a market cap of 500.7M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while TCMD trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas TCMD's P/E ratio is 20.56. In terms of profitability, ECOR's ROE is +5.25%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ECOR vs NPCE Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, NPCE has a market cap of 486.9M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while NPCE trades at $14.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas NPCE's P/E ratio is -25.05. In terms of profitability, ECOR's ROE is +5.25%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ECOR is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NPCE's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ECOR vs SGHT Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SGHT has a market cap of 436.4M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SGHT trades at $8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SGHT's P/E ratio is -14.32. In terms of profitability, ECOR's ROE is +5.25%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ECOR is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SGHT's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ECOR vs PACB Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, PACB has a market cap of 425.5M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while PACB trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas PACB's P/E ratio is -3.34. In terms of profitability, ECOR's ROE is +5.25%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ECOR is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PACB's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ECOR vs CLPT Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, CLPT has a market cap of 414.8M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while CLPT trades at $13.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas CLPT's P/E ratio is -11.72. In terms of profitability, ECOR's ROE is +5.25%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ECOR is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ECOR vs SENS Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SENS has a market cap of 400.4M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SENS trades at $9.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SENS's P/E ratio is -4.30. In terms of profitability, ECOR's ROE is +5.25%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ECOR is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ECOR vs OFIX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, OFIX has a market cap of 352.1M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while OFIX trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas OFIX's P/E ratio is -5.67. In terms of profitability, ECOR's ROE is +5.25%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ECOR is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
ECOR vs CV Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, CV has a market cap of 334.8M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while CV trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas CV's P/E ratio is -10.63. In terms of profitability, ECOR's ROE is +5.25%, compared to CV's ROE of -1.78%. Regarding short-term risk, ECOR is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check CV's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ECOR vs CATX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, CATX has a market cap of 327.3M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while CATX trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas CATX's P/E ratio is -2.16. In terms of profitability, ECOR's ROE is +5.25%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ECOR is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check CATX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ECOR vs TLSI Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, TLSI has a market cap of 314M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while TLSI trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas TLSI's P/E ratio is -3.04. In terms of profitability, ECOR's ROE is +5.25%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ECOR is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check TLSI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ECOR vs SMLR Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ECOR's ROE is +5.25%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ECOR is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ECOR vs TMCI Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, TMCI has a market cap of 291.3M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while TMCI trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas TMCI's P/E ratio is -4.78. In terms of profitability, ECOR's ROE is +5.25%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ECOR is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TMCI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ECOR vs RCEL Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, RCEL has a market cap of 273.8M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while RCEL trades at $11.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas RCEL's P/E ratio is -7.65. In terms of profitability, ECOR's ROE is +5.25%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ECOR is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check RCEL's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ECOR vs INFU Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, INFU has a market cap of 258.3M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while INFU trades at $12.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas INFU's P/E ratio is 31.22. In terms of profitability, ECOR's ROE is +5.25%, compared to INFU's ROE of +0.15%. Regarding short-term risk, ECOR is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ECOR vs MGRM Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ECOR's ROE is +5.25%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ECOR is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
ECOR vs NVRO Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ECOR's ROE is +5.25%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ECOR is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NVRO's competition here
Electromed, Inc. (AMEX: ELMD)
ECOR vs ELMD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ELMD has a market cap of 218.5M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ELMD trades at $26.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ELMD's P/E ratio is 20.15. In terms of profitability, ECOR's ROE is +5.25%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ECOR is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ELMD's competition here
RxSight, Inc. (NASDAQ: RXST)
ECOR vs RXST Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, RXST has a market cap of 215.3M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while RXST trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas RXST's P/E ratio is -4.60. In terms of profitability, ECOR's ROE is +5.25%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ECOR is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
ECOR vs PROF Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, PROF has a market cap of 212.9M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while PROF trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas PROF's P/E ratio is -5.98. In terms of profitability, ECOR's ROE is +5.25%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ECOR is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check PROF's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ECOR vs STIM Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, STIM has a market cap of 201.8M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while STIM trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas STIM's P/E ratio is -6.59. In terms of profitability, ECOR's ROE is +5.25%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ECOR is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ECOR vs BSGM Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ECOR's ROE is +5.25%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ECOR is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ECOR vs MDGS Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ECOR's ROE is +5.25%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ECOR is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ECOR vs QIPT Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ECOR's ROE is +5.25%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ECOR is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ECOR vs FOCL Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, FOCL has a market cap of 155.6M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while FOCL trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas FOCL's P/E ratio is -4.01. In terms of profitability, ECOR's ROE is +5.25%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, ECOR is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check FOCL's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ECOR vs LUCD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, LUCD has a market cap of 149.9M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while LUCD trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas LUCD's P/E ratio is -2.12. In terms of profitability, ECOR's ROE is +5.25%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, ECOR is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check LUCD's competition here
Quantum-Si incorporated (NASDAQ: QSI)
ECOR vs QSI Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, QSI has a market cap of 147.4M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while QSI trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas QSI's P/E ratio is -1.62. In terms of profitability, ECOR's ROE is +5.25%, compared to QSI's ROE of -0.47%. Regarding short-term risk, ECOR is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check QSI's competition here
Quanterix Corporation (NASDAQ: QTRX)
ECOR vs QTRX Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, QTRX has a market cap of 144.6M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while QTRX trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas QTRX's P/E ratio is -1.21. In terms of profitability, ECOR's ROE is +5.25%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ECOR is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check QTRX's competition here
Inogen, Inc. (NASDAQ: INGN)
ECOR vs INGN Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, INGN has a market cap of 139.2M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while INGN trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas INGN's P/E ratio is -5.65. In terms of profitability, ECOR's ROE is +5.25%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ECOR is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
ECOR vs ICAD Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ECOR's ROE is +5.25%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ECOR is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ECOR vs HJLI Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas HJLI's P/E ratio is N/A. In terms of profitability, ECOR's ROE is +5.25%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ECOR is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
ECOR vs ASXC Comparison September 2026
electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECOR stands at 105.3M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ECOR is priced at $11.68 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECOR currently has a P/E ratio of -6.95, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ECOR's ROE is +5.25%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, ECOR is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ASXC's competition here